Steven P. Treon, MD, PhD: The rationale behind targeted therapies that you’re really getting at the Achilles’ heel of the tumor itself. You want to be able to rationally shut down the pathway that’s ...
In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the ...
CLR 131 shows promise in treating relapsed/refractory Waldenstrom’s macroglobulinemia, targeting B-cell malignancies with iodine-131 delivery. The trial will enroll 50 patients, administering up to ...
(RTTNews) - Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton's ...
Waldenstrom macroglobulinemia (WM) is a rare type of cancer that affects the immune system. There are numerous treatments that may help, such as chemotherapy, immunotherapy, targeted drug therapy, and ...
Cellectar Biosciences, Inc. announced its intention to seek conditional approval from the European Medicines Agency (EMA) for its drug iopofosine I 131 to treat Waldenstrom Macroglobulinemia, ...
Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase ...
Schrodinger has won U.S. Food and Drug Administration fast-track designation for its SGR-1505 drug candidate in a rare type of non-Hodgkin's lymphoma. Schrodinger on Friday said the designation covers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results